These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19351226)

  • 21. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
    Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
    Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
    Jaworowski S; Benarroch F; Gross-Tsur V
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):365-70. PubMed ID: 16768644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E; Souverein P; Swaab H; van Engeland H; Heerdink R; Egberts T
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder.
    Vaughan B; Fegert J; Kratochvil CJ
    Expert Opin Pharmacother; 2009 Mar; 10(4):669-76. PubMed ID: 19239401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.
    Savill NC; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill D
    CNS Drugs; 2015 Feb; 29(2):131-51. PubMed ID: 25698145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
    Bushe CJ; Savill NC
    J Psychopharmacol; 2014 Mar; 28(3):204-11. PubMed ID: 23438503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
    Cunill R; Castells X; Tobias A; Capellà D
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
    Bushe C; Day K; Reed V; Karlsdotter K; Berggren L; Pitcher A; Televantou F; Haynes V
    J Psychopharmacol; 2016 May; 30(5):444-58. PubMed ID: 27005307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D; Plosker GL
    CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atomoxetine--treatment of attention deficit hyperactivity disorder: beyond stimulants.
    Thomason C; Michelson D
    Drugs Today (Barc); 2004 May; 40(5):465-73. PubMed ID: 15319800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
    Panei P; Arcieri R
    Recenti Prog Med; 2013 Jun; 104(6):254-61. PubMed ID: 23801229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
    Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
    Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.